Pathogenic mechanisms and experimental models of multiple sclerosis

Loss of STAT3 in CD4 + T Cells Prevents Development of Experimental Autoimmune Diseases

(2014) Xuebin Liu et al.   JOURNAL OF IMMUNOLOGY

Cutting Edge: Central Nervous System Plasmacytoid Dendritic Cells Regulate the Severity of Relapsing Experimental Autoimmune Encephalomyelitis

(2014) S. L. Bailey-Bucktrout et al.   JOURNAL OF IMMUNOLOGY

Cutting Edge: Th1 Cells Facilitate the Entry of Th17 Cells to the Central Nervous System during Experimental Autoimmune Encephalomyelitis

(2014) R. A. O'Connor et al.   JOURNAL OF IMMUNOLOGY

Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial

(2009) Kathleen Hawker et al.   ANNALS OF NEUROLOGY

The challenge of multiple sclerosis: How do we cure a chronic heterogeneous disease?

(2009) Howard L. Weiner   ANNALS OF NEUROLOGY

Altered innate immune response of plasmacytoid dendritic cells in multiple sclerosis

(2009) A. Bayas et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

The Contribution of γδ T Cells to the Pathogenesis of EAE and MS

(2009) Sarah Blink et al.   CURRENT MOLECULAR MEDICINE

Replication analysis identifies TYK2 as a multiple sclerosis susceptibility factor

(2009) Maria Ban et al.   EUROPEAN JOURNAL OF HUMAN GENETICS

EAE: An immunologist's magic eye

(2009) Gurumoorthy Krishnamoorthy et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Interleukin-1 and IL-23 Induce Innate IL-17 Production from γδ T Cells, Amplifying Th17 Responses and Autoimmunity

(2009) Caroline E. Sutton et al.   IMMUNITY

Spontaneous relapsing-remitting EAE in the SJL/J mouse: MOG-reactive transgenic T cells recruit endogenous MOG-specific B cells

(2009) Bernadette Pöllinger et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Th1, Th17, and Th9 Effector Cells Induce Experimental Autoimmune Encephalomyelitis with Different Pathological Phenotypes

(2009) A. Jager et al.   JOURNAL OF IMMUNOLOGY

Peripheral blood CD4+ T lymphocytes from multiple sclerosis patients are characterized by higher PSGL-1 expression and transmigration capacity across a human blood-brain barrier-derived endothelial cell line

(2009) Bouchaib Bahbouhi et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Expression of TH1 and TH17 cytokines and transcription factors in multiple sclerosis patients: Does baseline T-Bet mRNA predict the response to interferon-beta treatment?

(2009) Jelena Drulovic et al.   JOURNAL OF NEUROIMMUNOLOGY

Interferon-beta-1a treatment increases CD56bright natural killer cells and CD4+CD25+ Foxp3 expression in subjects with multiple sclerosis

(2009) Arthur A. Vandenbark et al.   JOURNAL OF NEUROIMMUNOLOGY

Glatiramer acetate improves regulatory T-cell function by expansion of naive CD4+CD25+FOXP3+CD31+ T-cells in patients with multiple sclerosis

(2009) Juergen Haas et al.   JOURNAL OF NEUROIMMUNOLOGY

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial

(2009) G Comi et al.   LANCET

Buzz around Campath proof-of-concept trial in MS

(2009) Randy Osborne   NATURE BIOTECHNOLOGY

Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci

(2009) Philip L De Jager et al.   NATURE GENETICS

Oral fingolimod (FTY720) in multiple sclerosis: Two-year results of a phase II extension study

(2009) P. O'Connor et al.   NEUROLOGY

Reduction of Disease Activity and Disability With High-Dose Cyclophosphamide in Patients With Aggressive Multiple Sclerosis

(2008) Chitra Krishnan et al.   ARCHIVES OF NEUROLOGY

The expanding genetic overlap between multiple sclerosis and type I diabetes

(2008)   GENES AND IMMUNITY

Variation within the CLEC16A gene shows consistent disease association with both multiple sclerosis and type 1 diabetes in Sardinia

(2008) M Zoledziewska et al.   GENES AND IMMUNITY

IL2RA and IL7RA genes confer susceptibility for multiple sclerosis in two independent European populations

(2008) F Weber et al.   GENES AND IMMUNITY

CD226 Gly307Ser association with multiple autoimmune diseases

(2008) J P Hafler et al.   GENES AND IMMUNITY

IL-12– and IL-23–modulated T cells induce distinct types of EAE based on histology, CNS chemokine profile, and response to cytokine inhibition

(2008) Mark A. Kroenke et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Neutralisation of IL12 p40 or IL23 p40 does not block inflammation in multiple sclerosis

(2008) Roland Martin   LANCET NEUROLOGY

Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study

(2008) Benjamin M Segal et al.   LANCET NEUROLOGY

Grey matter pathology in multiple sclerosis

(2008) Jeroen JG Geurts et al.   LANCET NEUROLOGY

B cells and multiple sclerosis

(2008) Diego Franciotta et al.   LANCET NEUROLOGY

Genetic variation in the KIF1B locus influences susceptibility to multiple sclerosis

(2008) Yurii S Aulchenko et al.   NATURE GENETICS

Differential regulation of central nervous system autoimmunity by TH1 and TH17 cells

(2008) Ingunn M Stromnes et al.   NATURE MEDICINE

Multiple Lessons for Multiple Sclerosis

(2008) Stephen L. Hauser   NEW ENGLAND JOURNAL OF MEDICINE

Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis

(2008)   NEW ENGLAND JOURNAL OF MEDICINE

B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis

(2008) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE

Identification and development of new therapeutics for multiple sclerosis

(2008) Ralf A. Linker et al.   TRENDS IN PHARMACOLOGICAL SCIENCES